Skip to content
Life Sciences Series B Founded 2007

Biofluidica

Provider of liquid biopsy tests using CTCs. The flagship system uses a capture bed coated with specific antibodies to capture and separate CTCs from blood samples for analysis. The system has been clinically validated for pancreatic cancer, colorectal cancer, ovarian cancer, and breast cancer. The company was founded in 2007 and headquartered in Chapel Hill, United States. It has raised $18.1M in series b funding,…

📍 Chapel Hill, United States · Oncology,

Funding snapshot

Last roundSeries B
Amount$18M
Date23 March 2022
Total raised$18M
Team size7

About

Provider of liquid biopsy tests using CTCs. The flagship system uses a capture bed coated with specific antibodies to capture and separate CTCs from blood samples for analysis. The system has been clinically validated for pancreatic cancer, colorectal cancer, ovarian cancer, and breast cancer. The company was founded in 2007 and headquartered in Chapel Hill, United States. It has raised $18.1M in series b funding, with backing from Mizzou, NIH, HHS. The company operates in the Life Sciences - Oncology, Life Sciences - Clinical Genomics, Life Sciences - Genomics space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Blood Cancer.

Business model

Oncology > In-Vitro Diagnostic Tests > Blood Cancer,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA

Institutional investors

Mizzou NIH HHS

Latest coverage

No articles yet.

Raising like Biofluidica?

Analyze your pitch deck before your next raise.

Analyze My Deck →